Research programme: NADPH oxidase inhibitors - GenKyoTexAlternative Names: GKT 831; GKT-03; GKT-136901; GKT-771; GKT-901; HTS programme; NOX inhibitors - GenKyoTex
Latest Information Update: 06 Jan 2017
At a glance
- Originator GenKyoTex
- Class Small molecules
- Mechanism of Action CYBB protein inhibitors; NADPH oxidase inhibitors; NOX1 protein inhibitors; NOX4 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Primary biliary cirrhosis
- Research Cancer; Inflammation; Pain
- No development reported Cardiovascular disorders; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Neurodegenerative disorders